These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 1615478

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V, Parquet A, Tahiri C, Claeyssens S, Potard V, Faradji A, Peynet J, Costagliola D, Suivi Thérapeutique National des Hémophiles Group.
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [Abstract] [Full Text] [Related]

  • 24. Viral safety of a new highly purified factor VIII (OCTATE).
    Biesert L, Lemon S, Goudeau A, Suhartono H, Wang L, Brede HD.
    J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
    [Abstract] [Full Text] [Related]

  • 25. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM, Emoclot15 Study Members.
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [Abstract] [Full Text] [Related]

  • 26. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K, Berntorp E, ten Cate JW, Johnsson H, Peters M, Savidge G, Tengborn L, Spira J, Stahl C.
    Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
    [Abstract] [Full Text] [Related]

  • 27. Viral safety of solvent-detergent treated blood products.
    Horowitz B, Prince AM, Horowitz MS, Watklevicz C.
    Dev Biol Stand; 1993 Feb; 81():147-61. PubMed ID: 8174797
    [Abstract] [Full Text] [Related]

  • 28. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
    Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M, Saint-Remy JM, Vermylen J.
    Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
    [Abstract] [Full Text] [Related]

  • 29. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA.
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [Abstract] [Full Text] [Related]

  • 30. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation.
    Raut S, Di Giambattista M, Bevan SA, Hubbard AR, Barrowcliffe TW, Laub R.
    Thromb Haemost; 1998 Oct; 80(4):624-31. PubMed ID: 9798982
    [Abstract] [Full Text] [Related]

  • 31. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).
    Stadler M, Gruber G, Kannicht C, Biesert L, Radomski KU, Suhartono H, Pock K, Neisser-Svae A, Weinberger J, Römisch J, Svae TE.
    Biologicals; 2006 Dec; 34(4):281-8. PubMed ID: 16500114
    [Abstract] [Full Text] [Related]

  • 32. Review of the hepatitis A epidemics in hemophiliacs in Europe.
    Vermylen J, Peerlinck K.
    Vox Sang; 1994 Dec; 67 Suppl 4():8-11; discussion 24-6. PubMed ID: 7831867
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
    Chtourou S, Porte P, Nogré M, Bihoreau N, Cheesman E, Samor B, Sauger A, Raut S, Mazurier C.
    Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
    [Abstract] [Full Text] [Related]

  • 38. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.
    Dichtelmüller H, Rudnick D, Breuer B, Kotitschke R, Kloft M, Darling A, Watson E, Flehmig B, Lawson S, Frösner G.
    Biologicals; 1996 Jun; 24(2):125-30. PubMed ID: 8889059
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
    Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J.
    Thromb Haemost; 1993 Feb 01; 69(2):115-8. PubMed ID: 8456422
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.